Agency Information Collection Activities: Proposed Collection; Comment Request, 42308-42309 [E9-20128]
Download as PDF
srobinson on DSKHWCL6B1PROD with NOTICES
42308
Federal Register / Vol. 74, No. 161 / Friday, August 21, 2009 / Notices
prescription drugs under the Medicare
Part D benefit to Medicare beneficiaries.
The data is used primarily for payment,
and is used for claim validation as well
as for other legislated functions such as
quality monitoring, program integrity
and oversight.
Form Number: CMS–10174 (OMB#:
0938–0982).
Frequency: Reporting—Monthly.
Affected Public: Business or other forprofits and not-for-profit institutions.
Number of Respondents: 747.
Total Annual Responses: 947,881,770.
Total Annual Hours: 1896.
(For policy questions regarding this
collection contact Bobbie Knickman at
410–786–4161. For all other issues call
410–786–1326.)
2. Type of Information Collection
Request: New collection.
Title of Information Collection:
Medicare Quality of Care Complaint
Form.
Use: In accordance with Section
1154(a)(14) of the Social Security Act,
Quality Improvement Organizations
(QIOs) are required to conduct
appropriate reviews of all written
complaints submitted by beneficiaries
concerning the quality of care received.
The Medicare Quality of Care Complaint
Form will be used by Medicare
beneficiaries to submit quality of care
complaints. This form will establish a
standard form for all beneficiaries to
utilize and ensure pertinent information
is obtained by QIOs to effectively
process these complaints.
Form Number: CMS–10287 (OMB#:
0938–New).
Frequency: Reporting—on occasion.
Affected Public: Individuals or
households.
Number of Respondents: 3,500.
Total Annual Responses: 3,500.
Total Annual Hours: 583.
(For policy questions regarding this
collection contact Tom Kessler at 410–
786–1991. For all other issues call 410–
786–1326.)
3. Type of Information Collection
Request: Extension of a currently
approved collection.
Title of Information Collection:
External Quality Review Protocols.
Use: The results of Medicare reviews,
Medicare accreditation services, and
Medicaid external quality reviews will
be used by States in assessing the
quality of care provided to Medicaid
beneficiaries by managed care
organizations and to provide
information on the quality of care
provided to the general public upon
request.
Form Number: CMS–R–305 (OMB#:
0938–0786).
Frequency: Reporting—Yearly.
VerDate Nov<24>2008
16:22 Aug 20, 2009
Jkt 217001
Affected Public: State, Local or Tribal
Governments.
Number of Respondents: 40.
Total Annual Responses: 40.
Total Annual Hours: 520,000.
(For policy questions regarding this
collection contact Gary B. Jackson at
410–786–1218. For all other issues call
410–786–1326.)
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS Web Site
address at https://www.cms.hhs.gov/
PaperworkReductionActof1995, or Email your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov, or call the
Reports Clearance Office on (410) 786–
1326.
To be assured consideration,
comments and recommendations for the
proposed information collections must
be received by the OMB desk officer at
the address below, no later than 5 p.m.
on September 21, 2009:
OMB, Office of Information and
Regulatory Affairs, Attention: CMS
Desk Officer, Fax Number: (202) 395–
6974, E-mail:
OIRA_submission@omb.eop.gov.
Dated: August 14, 2009.
Michelle Shortt,
Director, Regulations Development Group,
Office of Strategic Operations and Regulatory
Affairs.
[FR Doc. E9–20127 Filed 8–20–09; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10198]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
AGENCY: Centers for Medicare &
Medicaid Services.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare & Medicaid
Services (CMS) is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
performance of the agency’s functions;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
1. Type of Information Collection
Request: Extension without change of a
currently approved collection; Title of
Information Collection: Creditable
Coverage Disclosure to CMS On-Line
Form and Instructions; Use: Most
entities that currently provide
prescription drug benefits to any
Medicare Part D eligible individual
must disclose to the CMS whether the
prescription drug benefit that they offer
is creditable. The disclosure is required
to be provided annually and upon any
change that affects whether the coverage
is creditable prescription drug coverage.
CMS released a Disclosure to CMS
Guidance Paper and a disclosure to
CMS notification on-line form in
January 2006.
Section 1860D–1 of the Medicare
Prescription Drug, Improvement, and
Modernization Act of 2003 (MMA) and
implementing regulations at 42 CFR
423.56 requires that entities that offer
prescription drug benefits under any of
the types of coverage described in 42
CFR 423.56(b) provide a disclosure of
creditable coverage to CMS informing us
whether such coverage meets the
actuarial requirements specified in
guidelines provided by CMS. Form
Number: CMS–10198 (OMB#: 0938–
1013); Frequency: Reporting—Yearly
and Semi-annually; Affected Public:
Federal Government, Business or other
for-profits and not-for-profit
institutions, and State, Local, or Tribal
Governments; Number of Respondents:
87,500; Total Annual Responses:
87,500; Total Annual Hours: 7,291.7.
(For policy questions regarding this
collection contact James Mayhew at
410–786–9244. For all other issues call
410–786–1326.)
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS’ Web site
at https://www.cms.hhs.gov/
PaperworkReductionActof1995, or Email your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov, or call the
Reports Clearance Office on (410) 786–
1326.
In commenting on the proposed
information collections please reference
the document identifier or OMB control
number. To be assured consideration,
E:\FR\FM\21AUN1.SGM
21AUN1
Federal Register / Vol. 74, No. 161 / Friday, August 21, 2009 / Notices
comments and recommendations must
be submitted in one of the following
ways by October 20, 2009:
1. Electronically. You may submit
your comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) accepting comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number (CMS–10198), Room
C4–26–05, 7500 Security Boulevard,
Baltimore, Maryland 21244–1850.
Dated: August 14, 2009.
Michelle Shortt,
Director, Regulations Development Group,
Office of Strategic Operations and Regulatory
Affairs.
[FR Doc. E9–20128 Filed 8–20–09; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0391]
Clinical Investigator Training Course
AGENCY:
Food and Drug Administration,
HHS.
srobinson on DSKHWCL6B1PROD with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration’s (FDA’s) Office of
Critical Path Programs and the Clinical
Trials Transformation Initiative (CTTI)
are co-sponsoring a 3-day training
course for clinical investigators on
scientific, ethical, and regulatory
aspects of clinical trials. This training
course is intended to provide
investigators with expertise in the
design, conduct, and analysis of clinical
trials; improve the quality of clinical
trials; and enhance the safety of trial
participants. Senior FDA staff will
communicate directly with clinical
investigators on issues of greatest
importance for successful clinical
research.
DATES: The training course will be held
on November 16 and 17, 2009, from 8
a.m. to 5 p.m. and on November 18,
2009, from 8 a.m. to 3:30 p.m.
ADDRESSES: The course will be held at
the National Labor College, 10000 New
Hampshire Ave., Silver Spring, MD
20903.
FOR FURTHER INFORMATION CONTACT:
Devota DeMarco, Office of Critical Path
VerDate Nov<24>2008
16:22 Aug 20, 2009
Jkt 217001
42309
Programs (HF–18), Office of the
Commissioner, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–3605,
Devota.DeMarco@fda.hhs.gov; or
Nancy Stanisic, Office of Critical Path
Programs (HF–18), Office of the
Commissioner, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–1660,
Nancy.Stanisic@fda.hhs.gov.
Registration: Register by November 2,
2009, at the registration/information
Web site at https://www.trials
transformation.org/fda-clinicalinvestigator-training-course/ or by fax at
919–660–1769. Registration materials,
payment procedures, accommodation
information, and a detailed description
of the course can be found at the
registration/information Web site. The
registration fee is $300 per person. The
fee includes course materials and onsite
lunch. Early registration is
recommended because seating is
limited. There will be no onsite
registration. If you need special
accommodations due to a disability,
please contact one of the persons listed
in the FOR FURTHER INFORMATION
CONTACT section of this document.
SUPPLEMENTARY INFORMATION:
• The essential toxicological,
pharmacological, and manufacturing
data to support investigational use in
humans;
• Fundamental issues in the design
and conduct of clinical trials;
• Statistical and analytic
considerations in the interpretation of
trial data;
• Appropriate safety evaluation
during studies; and
• The ethical considerations and
regulatory requirements for clinical
trials.
In addition, the course should:
• Foster a cadre of clinical
investigators with knowledge,
experience, and commitment to
investigational medicine;
• Promote communication between
clinical investigators and FDA;
• Enhance investigators’
understanding of FDA’s role in
experimental medicine; and
• Improve the quality of data while
enhancing subject protection in the
performance of clinical trials.
I. Background
Clinical trial investigators play a
critical role in the development of
medical products. They bear the
responsibility for ensuring the safe and
ethical treatment of study subjects and
for acquiring adequate and reliable data
to support regulatory decisions. This
course is intended to assist clinical
investigators in understanding what
preclinical and clinical information is
needed to support the investigational
use of medical products, as well as the
scientific, regulatory, and ethical
considerations involved in the conduct
of clinical trials. The course will cover
a wide variety of key topics, including
material on novel safety concerns,
adverse event monitoring, compliance
with the legal and ethical obligations of
clinical research, and acceptable
scientific and analytic standards in the
design and conduct of clinical studies.
The faculty will include a diverse
representation of senior FDA staff,
enabling FDA to communicate directly
with clinical investigators on issues of
greatest importance for successful
clinical research.
The course will be conducted over 3
days and will comprise approximately
26 lectures, each lasting between 30 and
45 minutes. Two sessions of case
studies will be included for which
participants will be expected to do
preparatory reading and answer
questions. The course will be presented
mainly by senior FDA staff, with guest
lecturers presenting selected topics.
On day one, the course will address
the role of FDA in clinical studies,
regulatory considerations for clinical
trials, and review of the material
generally appearing in an ‘‘investigator’s
brochure,’’ i.e., the preclinical
information (toxicology, animal studies,
and chemistry/manufacturing
information) that supports initial
clinical trials in humans. Presentations
will also discuss the role of clinical
pharmacology in early clinical studies
and how this information is used in the
design of subsequent studies. Day two
will include discussions of scientific,
statistical, ethical, and regulatory
aspects of clinical studies. Day three
will include discussions of safety
assessment in clinical trials, including
hepatic and cardiovascular safety,
approaches to special populations (e.g.,
pregnant women and pediatrics), and
the role of personalized medicine and
new scientific techniques in medical
product development.
II. Description of the Training Course
A. Purpose
The training course is designed to
provide clinical investigators with an
overview of the following topics:
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
B. Proposed Agenda
E:\FR\FM\21AUN1.SGM
21AUN1
Agencies
[Federal Register Volume 74, Number 161 (Friday, August 21, 2009)]
[Notices]
[Pages 42308-42309]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-20128]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[Document Identifier: CMS-10198]
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Centers for Medicare & Medicaid Services.
In compliance with the requirement of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the Centers for Medicare & Medicaid
Services (CMS) is publishing the following summary of proposed
collections for public comment. Interested persons are invited to send
comments regarding this burden estimate or any other aspect of this
collection of information, including any of the following subjects: (1)
The necessity and utility of the proposed information collection for
the proper performance of the agency's functions; (2) the accuracy of
the estimated burden; (3) ways to enhance the quality, utility, and
clarity of the information to be collected; and (4) the use of
automated collection techniques or other forms of information
technology to minimize the information collection burden.
1. Type of Information Collection Request: Extension without change
of a currently approved collection; Title of Information Collection:
Creditable Coverage Disclosure to CMS On-Line Form and Instructions;
Use: Most entities that currently provide prescription drug benefits to
any Medicare Part D eligible individual must disclose to the CMS
whether the prescription drug benefit that they offer is creditable.
The disclosure is required to be provided annually and upon any change
that affects whether the coverage is creditable prescription drug
coverage. CMS released a Disclosure to CMS Guidance Paper and a
disclosure to CMS notification on-line form in January 2006.
Section 1860D-1 of the Medicare Prescription Drug, Improvement, and
Modernization Act of 2003 (MMA) and implementing regulations at 42 CFR
423.56 requires that entities that offer prescription drug benefits
under any of the types of coverage described in 42 CFR 423.56(b)
provide a disclosure of creditable coverage to CMS informing us whether
such coverage meets the actuarial requirements specified in guidelines
provided by CMS. Form Number: CMS-10198 (OMB: 0938-1013);
Frequency: Reporting--Yearly and Semi-annually; Affected Public:
Federal Government, Business or other for-profits and not-for-profit
institutions, and State, Local, or Tribal Governments; Number of
Respondents: 87,500; Total Annual Responses: 87,500; Total Annual
Hours: 7,291.7. (For policy questions regarding this collection contact
James Mayhew at 410-786-9244. For all other issues call 410-786-1326.)
To obtain copies of the supporting statement and any related forms
for the proposed paperwork collections referenced above, access CMS'
Web site at https://www.cms.hhs.gov/PaperworkReductionActof1995, or E-
mail your request, including your address, phone number, OMB number,
and CMS document identifier, to Paperwork@cms.hhs.gov, or call the
Reports Clearance Office on (410) 786-1326.
In commenting on the proposed information collections please
reference the document identifier or OMB control number. To be assured
consideration,
[[Page 42309]]
comments and recommendations must be submitted in one of the following
ways by October 20, 2009:
1. Electronically. You may submit your comments electronically to
https://www.regulations.gov. Follow the instructions for ``Comment or
Submission'' or ``More Search Options'' to find the information
collection document(s) accepting comments.
2. By regular mail. You may mail written comments to the following
address: CMS, Office of Strategic Operations and Regulatory Affairs,
Division of Regulations Development, Attention: Document Identifier/OMB
Control Number (CMS-10198), Room C4-26-05, 7500 Security Boulevard,
Baltimore, Maryland 21244-1850.
Dated: August 14, 2009.
Michelle Shortt,
Director, Regulations Development Group, Office of Strategic Operations
and Regulatory Affairs.
[FR Doc. E9-20128 Filed 8-20-09; 8:45 am]
BILLING CODE 4120-01-P